Table 2 Estimated average change per year over 4 years in absolute bronchodilator response (Δ, in ml) (±SE) for FEV 1 and FVC in the placebo arm of the UPLIFT trial by GOLD grading for airflow obstruction (I&II, III, IV), age (≤50 yrs, >50 yrs), gender, and smoking status (sustained ex-smoker, intermittent smoker, continuing smoker)
Group | FEV1 | FVC | ||
|---|---|---|---|---|
Estimated change in Δ (SE) per yr | p value | Estimated change in Δ (SE) per yr | p value | |
All | -10.9 (0.76) | <0.0001 | -20.6 (1.87) | <0.0001 |
GOLD Stage | ||||
I & II | -11.1 (1.10) | <0.0001 | -14.4 (2.42)1 | <0.0001 |
III | -11.2 (1.10) | <0.0001 | -25.2 (3.08) | <0.0001 |
IV | -13.1 (2.35) | <0.0001 | -40.6 (8.21) | <0.0001 |
Age, yrs | ||||
≤65 yrs | -11.6 (1.05) | <0.0001 | -15.5 (2.64)2 | <0.001 |
>65 yrs | -10.1 (1.09) | <0.0001 | -2.66 (2.60) | <0.0001 |
Gender | ||||
Male | -10.7 (0.92) | <0.0001 | -21.4 (2.27) | <0.0001 |
Female | -11.5 (1.21) | <0.0001 | -18.4 (2.98) | <0.0001 |
Smoking status | ||||
Sustained ex-smoker | -11.9 (0.93) 3 | <0.0001 | -24.6 (2.37)3 | <0.0001 |
Intermittent smoker | -10.5 (1.48) | <0.0001 | -17.3 (3.57) | <0.0001 |
Continuing smoker | -6.77 (2.42) | 0.0053 | -9.17 (5.70) | 0.11 |
Inhaled steroids (baseline) | ||||
No | -8.41 (1.24)4 | <0.0001 | -11.3 (3.01)4 | 0.0002 |
Yes | -12.5 (0.95) | <0.0001 | -26.6 (2.38) | <0.0001 |